Naomi Aronson, PhD, is Executive Director of Clinical Evaluation, Innovation, and Policy, Blue Cross and Blue Shield Association (BCBSA). Aronson leads BCBSA clinical effectiveness and policy engagement with government, regulatory agencies and policy consortia. Her areas of leadership include comparative effectiveness, patient centered research, safety surveillance, regulatory science and methodological standards.

Previously, Aronson led the development of the BCBSA Technology Evaluation Center (TEC) as a nationally recognized technology assessment program and an Evidence-based Practice Center (EPC) of the Agency for Healthcare Research and Quality (AHRQ).

Aronson is also a member of the Health Technology Assessment International Health Policy Forum, the National Academies of Sciences Genomics Roundtable, and the National Business Group on Health Committee on Evidence-Based Benefit Design. Prior to joining TEC, Aronson was a member of the Northwestern University faculty, specializing in the sociology of science and medicine. She also was a post-doctoral fellow in the Science, Technology and Society Program at the Massachusetts Institute  of Technology.

Conflicts of Interest

As of February 22, 2023

Financial or Business Associations:

  • Blue Cross Blue Shield Association, Employer

Personal Associations:

  • EXCITE International, Board Officer
  • FDA Heart Failure Collaboratory, Member
  • National Academy of Medicine Genomics Roundtable, Member
  • National Evaluation System for Health Technology Coordinating Center (NESTcc), Governing Committee
  • NESTcc Research Methods Subcommittee, Member
  • Health Technology Assessment International, Health Policy Forum, Member
  • Tapestry Networks, Committee/Work Group member
  • New drug development ParadIGmS (NEWDIGS), MIT Center for Biomedical Innovation, Member
  • BCBSA Medical Advisory Panel, Interim Chair
  • Multi-Cancer Early Detection Consortium, Member
  • Steering Committee Broader Value Initiative, Member


Person Type
Panel / Committee